Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer

Endometrial cancer stands as the predominant gynecological malignancy in developed nations. For advanced or recurrent disease, paclitaxel-based chemotherapy is the standard front-line therapy. However, paclitaxel resistance eternally develops. Based on the high prevalence of phosphatidylinositol-4,5...

Full description

Bibliographic Details
Main Authors: Yeong Gyu Jeong, Nar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, Sa Deok Hong, Seong Min Park, Seul-Gi Kim, Tae Hoen Kim, Yong Wha Moon
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Cancers
Subjects:
chemotherapy
PI3K pathway
endometrial cancer
drug resistance
paclitaxel resistance
eribulin
Online Access:https://www.mdpi.com/2072-6694/15/19/4887

Internet

https://www.mdpi.com/2072-6694/15/19/4887

Similar Items